Truist Financial Corp Trims Stock Position in Repligen Co. (NASDAQ:RGEN)

Truist Financial Corp lessened its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 11.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,953 shares of the biotechnology company’s stock after selling 378 shares during the period. Truist Financial Corp’s holdings in Repligen were worth $425,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the business. Wealth Enhancement Advisory Services LLC grew its position in Repligen by 133.2% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 4,009 shares of the biotechnology company’s stock valued at $597,000 after buying an additional 2,290 shares during the period. State of Alaska Department of Revenue grew its position in Repligen by 7.3% during the third quarter. State of Alaska Department of Revenue now owns 6,044 shares of the biotechnology company’s stock valued at $899,000 after buying an additional 410 shares during the period. QRG Capital Management Inc. grew its position in Repligen by 12.5% during the third quarter. QRG Capital Management Inc. now owns 3,642 shares of the biotechnology company’s stock valued at $542,000 after buying an additional 406 shares during the period. Equitable Trust Co. grew its position in Repligen by 52.8% during the third quarter. Equitable Trust Co. now owns 2,577 shares of the biotechnology company’s stock valued at $384,000 after buying an additional 891 shares during the period. Finally, Verdence Capital Advisors LLC grew its position in Repligen by 20.6% during the third quarter. Verdence Capital Advisors LLC now owns 3,808 shares of the biotechnology company’s stock valued at $567,000 after buying an additional 651 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Stock Performance

RGEN opened at $154.81 on Wednesday. The firm has a market capitalization of $8.67 billion, a PE ratio of -303.55, a PEG ratio of 4.54 and a beta of 0.99. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $203.13. The firm’s 50-day moving average price is $156.52 and its 200 day moving average price is $148.48. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company had revenue of $167.55 million for the quarter, compared to the consensus estimate of $167.58 million. As a group, sell-side analysts expect that Repligen Co. will post 1.72 EPS for the current fiscal year.

Analysts Set New Price Targets

RGEN has been the topic of several research analyst reports. StockNews.com lowered shares of Repligen from a “hold” rating to a “sell” rating in a research report on Friday, February 21st. HC Wainwright reiterated a “buy” rating and issued a $180.00 target price on shares of Repligen in a research report on Friday, February 21st. Wolfe Research initiated coverage on shares of Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating on the stock. Royal Bank of Canada lifted their target price on shares of Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research report on Friday, February 21st. Finally, JPMorgan Chase & Co. lifted their target price on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. One analyst has rated the stock with a sell rating, five have given a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Repligen has a consensus rating of “Moderate Buy” and a consensus target price of $181.00.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.